IL17A and psoriasis: The advantages of IL-17 signaling inhibitors include their good tolerance together with high levels of effectiveness, with more than 80% of the patients achieving 75% improvement on the Psoriasis Area and Severity Index (PASI75) and more than 68% reaching PASI90, from a 3-month treatment which persists up to a year (reviewed in [11]).